Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease

被引:0
作者
Jenny Avarappattu
Ariana Gaspert
Giuseppina Spartà
Marianne Rohrbach
机构
[1] University Children’s Hospital Zurich,Department of Metabolic Medicine and Department of Nephrology
[2] University Hospital Zurich,Department of Pathology and Molecular Pathology
来源
Pediatric Nephrology | 2024年 / 39卷
关键词
Fabry Disease; Enzyme replacement therapy; Kidney biopsy; Podocyte; Children;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:131 / 140
页数:9
相关论文
共 355 条
[1]  
Ries M(2005)Pediatric Fabry disease Pediatrics 115 e344-355
[2]  
Gupta S(2008)Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria Am J Kidney Dis 51 767-776
[3]  
Moore DF(2019)Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients Clin Genet 96 107-117
[4]  
Sachdev V(2017)Characterization of classical and nonclassical Fabry disease: a multicenter study J Am Soc Nephrol 28 1631-1641
[5]  
Quirk JM(2008)Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry Pediatr Res 64 550-555
[6]  
Murray GJ(2007)Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry J Inherit Metab Dis 30 184-192
[7]  
Rosing DR(2015)Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria Nephron 129 16-21
[8]  
Robinson C(2012)Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey Clin Genet 81 485-490
[9]  
Schaefer E(2006)Manifestations of Fabry disease in placental tissue J Inherit Metab Dis 29 106-111
[10]  
Gal A(2007)Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents J Clin Pharmacol 47 1222-1230